Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Pancreatic neuroendocrine tumours, drawn from the whole corpus: 18 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The best order of radioligand therapy, everolimus, sunitinib, cabozantinib and CAPTEM is unknown.
Which small non-functioning tumours can safely be watched rather than resected.
MGMT and other predictors of CAPTEM response are not validated for decisions.
Grade 3 well-differentiated tumours sit between the tumour and carcinoma paradigms and need their own trials.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Advanced pancreatic and extra-pancreatic neuroendocrine tumours after prior therapy (CABINET)
PFS 23.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.